Istaroxime follow-on compounds: A new class of selective SERCA2a activators for chronic heart failure treatment.
Arici M, Hsu SC, Ferrandi M, Barassi P, Ronchi C, Torre E, Luraghi A, Metallo A, Chang GJ, Ferrari P, Bianchi G, Regonesi ME, Airoldi C, Peri F, Zaza A, Rocchetti M.
Arici M, et al. Among authors: peri f.
Vascul Pharmacol. 2024 Jun;155:107295. doi: 10.1016/j.vph.2024.107295.
Vascul Pharmacol. 2024.
PMID: 38985597
No abstract available.